申请人:Pfizer Inc.
公开号:US06150377A1
公开(公告)日:2000-11-21
The present invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, and R.sup.11 are as defined herein. The above compounds of formula 1 are useful in the treatment of hyperproliferative disorders, such as cancer, in mammals. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of formula 1 to a mammal requiring such treatment.
本发明涉及式1的化合物及其药学上可接受的盐、前药和溶剂化物,其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6、R.sup.7、R.sup.8、R.sup.9、R.sup.10和R.sup.11的定义如本文所述。式1的上述化合物在哺乳动物中用于治疗高增殖性疾病,如癌症。本发明还涉及含有式1的化合物的制药组合物,以及通过向需要此类治疗的哺乳动物给予式1的化合物来抑制异常细胞生长,包括癌症的方法。